In certain instances, these trials have revealed that anti-DR5 mAb treatments could induce stable disease in patients with GI malignancies and reduced tumor burden in cases of granulosa ovarian cancer and chondrosarcoma, but not in other tumor types [36, 37]. The gene discussed is TNFRSF10B; the disease is chondrosarcoma.